Articles tagged with Growth Factor Stimulation
Researchers develop biodegradable nanobone material that activates body's own healing properties to regrow bone, reducing need for invasive procedures. The material generates 80% more new bone than a material control and activates a key bone-repair growth factor with 10 times the level achieved using conventional methods.
Researchers found that synthetic PIC gel can stimulate cell growth and increase collagen production, potentially improving wound healing after pelvic organ prolapse surgery. The study also showed a mild immune response to the gel when tested on laboratory animals.
A new study published in the Journal of Dairy Science finds that feeding transition milk to neonatal Holstein calves instead of milk replacer improves health scores and stimulates intestinal development. The researchers found increased weight gain and improved gut health, with benefits seen in all sections of the small intestine.
Researchers found that severe asthma patients produce growth factors that block corticosteroids from working, leading to frequent breathing problems. This discovery may lead to new treatments targeting these growth factors to improve outcomes for patients with severe asthma.
Researchers at Terasaki Institute for Biomedical Innovation have developed a flexible, antibacterial conductive hydrogel-ePatch that accelerates wound healing with minimal side effects. The e-Patch uses silver nanowires and alginate to promote cell proliferation and migration, resulting in faster wound closure and reduced scarring.
Scientists have developed a method to produce strigolactones, a group of plant hormones that prevent excessive budding and branching. By combining yeast and bacteria, researchers can synthesize these hormones from microbes, providing a promising alternative to traditional methods.
Researchers at University of Delaware develop new biomaterials platform to stimulate growth factor expression and enhance chronic wound repair. The approach aims to provide a more efficient and localized production of growth factors, promoting full wound closure.
Researchers found that fruit flies can remember and crave sweeter, energy-rich foods. A growth factor controlling brain vessel formation also stimulates mouse and human neural stem cells to produce new brain cells.
Researchers at EPFL have developed bioengineered growth factors that significantly enhance wound healing, bone repair, and new blood vessel formation. The engineered growth factors display improved binding affinity to extracellular matrix proteins, leading to faster tissue closure and granulation tissue production.
A phase 2 study found that GM-CSF therapy did not improve treadmill walking time in patients with intermittent claudication, a common symptom of peripheral artery disease. The treatment may still warrant further investigation due to observed secondary outcomes.
Researchers at University of Western Ontario developed a strategy to stimulate blood vessel formation in tissues lacking oxygen, potentially treating conditions like coronary artery disease. The approach, using fibroblast growth factor 9 (FGF9), activates supporting cells that create functional new vessels that last over a year.
Researchers found that GM-CSF treatment increased circulating endothelial progenitor cells, improving walking ability without pain. The therapy also showed promise for reducing vascular function risk and atherosclerosis.
Researchers found that GM-CSF treatment significantly improved Crohn's disease symptoms in patients, suggesting a defect in innate immune system is the underlying cause. The study supports a new understanding of Crohn's and offers hope for a new treatment option.
Transforming growth factor-alpha (TGF-α) has emerged as a paradigmatic growth factor, defining cell- and context-specific actions attributed to many growth factors. Dr. Anita Roberts will discuss TGF-α's role in wound healing, autoimmune disease, fibrosis, and cancer, and several therapeutic strategies based on the growth factor.
Researchers have found that PR39 promotes angiogenesis by blocking the degradation of a key transcription factor, HIF-1alpha. The newly formed vessels were fully functional in mice studies, offering a promising tool for treating coronary artery disease and peripheral vascular disease.